SCHEMBL2118284

SCHEMBL2118284

NC(=O)c1ccc([N+](=O)[O-])s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.55
SMN1; SMN2 Q16637 6/20 0.51
LMNA P02545 6/20 0.50
HTT P42858 5/20 0.50
RAB9A P51151 3/20 0.50
F2 P00734 1/20 0.50
MAPT P10636 5/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
KMT2A Q03164 5/20 0.48
ALDH1A1 P00352 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
TP53 P04637 1/20 0.48
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
HSP90AA1 P07900 1/20 0.48
RECQL P46063 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30270357 0.82 ATM (0.50) ATMSMN1; SMN2LMNAHTTRAB9A
SCHEMBL218867 0.82 SMN1; SMN2 (0.53) ATMSMN1; SMN2LMNAHTTRAB9A
SCHEMBL6736049 0.80 SMN1; SMN2 (0.51) ATMSMN1; SMN2LMNAHTTRAB9A
SCHEMBL1937600 0.80 LMNA (0.54) ATMSMN1; SMN2LMNAHTTRAB9A
Hydrochloric Acid SCHEMBL7036575 0.80 SMN1; SMN2 (0.51) ATMSMN1; SMN2LMNAHTTRAB9A
SCHEMBL23529356 0.80 SMN1; SMN2 (0.53) ATMSMN1; SMN2LMNAHTTRAB9A
SCHEMBL27938343 0.79 SMN1; SMN2 (0.54) ATMSMN1; SMN2LMNAHTTRAB9A
SCHEMBL6261682 0.79 SMN1; SMN2 (0.59) SMN1; SMN2LMNAHTTRAB9AMAPT
SCHEMBL22493028 0.78 SMN1; SMN2 (0.57) ATMSMN1; SMN2LMNAHTTRAB9A
SCHEMBL23561312 0.76 LMNA (0.48) ATMSMN1; SMN2LMNAHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114667282-B Pyrimidine amide compounds and methods of treating cancer 昊运股份有限公司 2024-09-03 CN claimed
US-9949970-B2 Synthesis of new benzothiazole derivatives as potential anti-tubercular agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2018-04-24 US claimed
US-20160175303-A1 SYNTHESIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-06-23 US claimed
US-20120095021-A1 SYNTHSIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2012-04-19 US claimed
EP-0186252-B1 USE OF THIOPHENE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT AGAINST TUMOURS CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1992-04-01 EP claimed
CN-114667282-B Pyrimidine amide compounds and methods of treating cancer 昊运股份有限公司 2024-09-03 CN disclosed
CN-114667282-A Pyrimidine amide compounds and methods of treating cancer 昊运股份有限公司 2022-06-24 CN disclosed
US-10071995-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-09-11 US disclosed
EP-3197889-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma AG (DE) 2018-08-01 EP disclosed
EP-3197889-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma AG (DE) 2018-08-01 EP disclosed
US-20180127401-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-10 US disclosed
US-20180127401-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-10 US disclosed
CN-1440412-A Thienopyrrolidinones HOFFMANN LA ROCHE (CH) 2003-09-03 CN disclosed
EP-1301517-A1 THIENOPYRROLIDINONES F. HOFFMANN-LA ROCHE AG (CH) 2003-04-16 EP disclosed
US-6528653-B2 E.g., 4,6-dihydro 4-(heterocyclic ring-methylene)thieno(2,3-b) pyrrolidin-5-one derivatives; tumor necrosis factor ) inhibitors; anticarcinogenic, -proliferative and -arthritic agents; Alzheimer's disease; cardiovascular disorders HOFFMANN-LA ROCHE, INC. 2003-03-04 US disclosed
US-20020028841-A1 Thienopyrrolidinones F. HOFFMANN-LA ROCHE AG (CH) 2002-03-07 US disclosed
WO-2002002567-A1 THIENOPYRROLIDINONES F. HOFFMANN-LA ROCHE AG (CH) 2002-01-10 WO disclosed
EP-0186252-B1 USE OF THIOPHENE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT AGAINST TUMOURS CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1992-04-01 EP disclosed
US-4767758-A RADIOSENSITIZING CELLS; BLOCKING REACTION OF OXYGEN RADICALS CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1988-08-30 US disclosed
EP-0186252-A2 Use of thiophene compounds for the manufacture of a medicament against tumours CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1986-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127401-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, PNPO, VASP ATM 1448/4885SMN1; SMN2 3201/4885LMNA 2253/4885
US-20160175303-A1 SYNTHESIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS TST, TBCA, SDHA ATM 1657/4885SMN1; SMN2 4865/4885LMNA 3273/4885
US-20120095021-A1 SYNTHSIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS TST, SDHB, SDHA ATM 635/4885SMN1; SMN2 3952/4885LMNA 3375/4885
US-10071995-B2 Substituted oxopyridine derivatives OGFOD1, PNPO, VASP ATM 1448/4885SMN1; SMN2 3201/4885LMNA 2253/4885
US-20020028841-A1 Thienopyrrolidinones TNF, TYMP, TNFRSF1A ATM 2257/4885SMN1; SMN2 342/4885LMNA 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.